CM
AMPH icon

Castleark Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Castleark Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-192,649
Closed -$6.7M – 288
2022
Q2 		$6.7M Buy
+192,649
New +$6.87M 0.36% 53

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Castleark Management's AMPH Position: Q3 2022 in Review

Castleark Management sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2022, closing a stake of 192,649 shares — an estimated $6.7M sold.

Castleark Management first reported a position in AMPH in Q2 2022 and held it in 1 quarter. The position peaked at $6.7M in Q2 2022. 205 funds tracked by Wall St. Rank hold AMPH as of Q3 2022.

  • Castleark Management reported no remaining Amphastar Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Castleark Management sold 192,649 Amphastar Pharmaceuticals shares in Q3 2022, an estimated $6.7M.
  • Castleark Management first reported a position in Amphastar Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Castleark Management's Amphastar Pharmaceuticals position peaked at $6.7M in Q2 2022.
  • 205 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2022.

Based on Castleark Management's 13F filing for Q3 2022, filed 15 Nov 2022.